

**Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.**

Andrew Muir, Fred Poordad, John Mchutchison, Mitchell Shiffman, Thomas Berg, Peter Ferenci, E Jenny Heathcote, Jean-Michel Pawlotsky, Stefan Zeuzem, Henk Reesink, et al.

► **To cite this version:**

Andrew Muir, Fred Poordad, John Mchutchison, Mitchell Shiffman, Thomas Berg, et al.. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.. Hepatology, Wiley-Blackwell, 2011, 54 (5), pp.1538-46. 10.1002/hep.24549 . inserm-00647300

**HAL Id: inserm-00647300**

**<https://www.hal.inserm.fr/inserm-00647300>**

Submitted on 1 Nov 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Table 3. Adverse Events Leading to Discontinuation and Most Common Adverse Events Reported According to Treatment Group**

	<b>T12PR24</b>	<b>T12PR48</b>	<b>Unassigned*</b>	<b>Total</b>
n (%)	<b>N = 81</b>	<b>N = 34</b>	<b>N = 2</b>	<b>N = 117</b>
Adverse events leading to discontinuation**	5 (6)	3 (9)	2 (100)	10 (9)
Rash events‡	4 (5)	1 (3)	1 (50)	6 (5)
Pruritus	1 (1)	0 (0)	1 (50)	2 (2)
Pyrexia	1 (1)	1 (3)	0 (0)	2 (2)
Anemia	2 (2)	0 (0)	0 (0)	2 (2)
Adverse events occurring in >10% of patients, n (%)				
Severe adverse event	12 (15)	7 (21)	1 (50)	20 (17)
<b>General disorder</b>				
Fatigue	30 (37)	21 (62)	1 (50)	52 (44)
Influenza-like illness	17 (21)	10 (29)	1 (50)	28 (24)
Pyrexia	16 (20)	6 (18)	0 (0)	22 (19)
Chills	11 (14)	4 (12)	0 (0)	15 (13)
Asthenia	9 (11)	3 (9)	0 (0)	12 (10)
<b>Gastrointestinal disorder</b>				
Nausea	20 (25)	11 (32)	1 (50)	32 (27)
Diarrhea	19 (24)	6 (18)	0 (0)	25 (21)
Hemorrhoids	9 (11)	4 (12)	0 (0)	13 (11)
<b>Skin and subcutaneous disorders</b>				
Pruritus	34 (42)	9 (26)	2 (100)	45 (38)
Rash†	23 (28)	13 (38)	1 (50)	37 (32)
Dry skin	10 (12)	5 (15)	0 (0)	15 (13)
<b>Nervous system disorders</b>				
Headache	23 (28)	14 (41)	0 (0)	37 (32)
<b>Psychiatric disorders</b>				
Insomnia	14 (17)	7 (21)	1 (50)	22 (19)
Depression	9 (11)	4 (12)	0 (0)	13 (11)
<b>Musculoskeletal disorders</b>				
Myalgia	10 (12)	5 (15)	0 (0)	15 (13)
Arthralgia	11 (14)	2 (6)	0 (0)	13 (11)
<b>Respiratory disorders</b>				
Cough	9 (11)	4 (12)	2 (100)	15 (13)
<b>Blood and lymphatic disorders</b>				
Anemia	22 (27)	7 (21)	0 (0)	29 (25)

\*Unassigned patients discontinued treatment prior to week 12 assignment of treatment duration.

\*\*Adverse events leading to discontinuation in  $\geq 2$  patients.

‡This category includes all patients experiencing rash events as assessed with the use of a group of related terms to identify all dermatologic events. All treatment discontinuations due to rash happened during telaprevir phase.

†Using a variety of descriptive terms to identify all dermatologic events, rash events occurred in 44%, 53%, 100%, and 48% of T12PR24, T12PR48, Unassigned, and Total patients, respectively.